Australia's most trusted
source of pharma news
Thursday, 21 November 2024
Posted 21 November 2024 AM
People with osteoporosis now have better options for treatment, with Amgen's Evenity moving up to the first line from the start of this month, with the potential to halve the disease burden.
It makes Evenity the first osteoanabolic agent with dual mode of action listed on PBS as a first line of therapy for Australians with severe osteoporosis. It means patients can access the humanised monoclonal antibody after one fracture, instead of having to wait for a second.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.